Immune Responses in Hen's Egg Oral Immunotherapy
Primary Purpose
Food Allergy, Egg Protein Allergy, Immune Tolerance
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Hen's egg OIT
Sponsored by
About this trial
This is an interventional treatment trial for Food Allergy focused on measuring Food allergy, Hen's egg allergy, Desensitization, Oral immunotherapy (OIT), Systems biology
Eligibility Criteria
Inclusion Criteria:
- Age 6-19 years
- Sensitization to egg white (egg white- specific IgE ≥0.35 kU/l or skin prick test ≥3 mm)
- Positive double-blind, placebo-controlled food challenge to heated egg white
Exclusion Criteria:
- Poor adherence
- Uncontrolled or severe asthma
- Severe systemic illness
- Active autoimmune disease
- Active, malignant neoplasia
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Hen's egg OIT
Hen's egg avoidance
Arm Description
Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
Hen's egg is avoidance diet is continued.
Outcomes
Primary Outcome Measures
OIT-induced allergen-specific antibody responses
The amount of specific serum IgE, IgG4, and IgA antibodies (kU/L) to the major egg allergens (Gal d1 - d4) will be measured by ImmunoCAP after 0, 14, and 32 weeks of OIT or avoidance.
OIT-induced changes in the peripheral blood cell transcriptome
Gene expression of blood mononuclear cells (PBMC) after 0, 14 and 32 weeks of OIT or avoidance will be studied. Total-RNA extracted from PBMCs will be used for microarrays. The genome-wide expression of the approximately 25.000 genes will be investigated on Agilent SurePrint G3 Human Gene Expression v3 arrays.
OIT-induced allergen-specific expression profiles of messenger-RNAs and microRNAs
Comprehensive highthroughput sequencing for long (mRNA) and short (miRNA) coding gene expression approach will be used to investigate transcriptional changes in exposed blood cells after different stimulations (egg extract, LPS, PolyI:C)
Secondary Outcome Measures
The prorportion of participants able to consume 1000mg of egg protein after 32 weeks of OIT
Measured in mg of egg protein consumed without symptoms
Full Information
NCT ID
NCT03744325
First Posted
November 12, 2018
Last Updated
November 15, 2018
Sponsor
Helsinki University Central Hospital
Collaborators
University of Helsinki
1. Study Identification
Unique Protocol Identification Number
NCT03744325
Brief Title
Immune Responses in Hen's Egg Oral Immunotherapy
Official Title
Humoral and Cellular Immune Responses in Hen's Egg Oral Immunotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 18, 2014 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital
Collaborators
University of Helsinki
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study determines how a 6 months oral immunotherapy (OIT) program with hen's egg (HE) effects cellular and humoral immune responses in 50 children with HE allergy. Clinical data, transcriptomics and epigenetics are combined and analyzed by advanced system biology methods. This study will provide better understanding of the effects and mechanisms of OIT.
Detailed Description
Oral immunotherapy (OIT) is a therapeutic approach, where gradually increasing doses of a specific food allergen are administered orally. OIT can desensitize up to 80% of children with persistent food allergy, and in a subset lead to sustained immune tolerance. The immunologic mechanisms induced by OIT are still poorly understood.
In this randomized cross-over study, 50 children with challenge-confirmed hen's egg (HE) allergy will be randomized (2:1) to receive either active HE OIT or continue on an avoidance diet for 6 months after which active OIT is started. The immunological changes induced by OIT will be compared to the patient's initial status and to that of the patients on an avoidance diet.
Serum antibody and humoral mediator analyses as well as gene expression of blood mononuclear cell (PBMC) by genome-wide microarray assays will be studied. PBMCs will be stimulated with HE allergens and innate immunity agonists, and the differences in the expression profiles of messenger-RNAs as well as microRNAs will be studied. Single-cell sequencing and sorting of regulator T cells (Tregs) will be performed focusing on their transcriptomic responses and gene methylation. Finally, clinical data, transcriptomics and epigenetic changes will be combined and analyzed by advanced system biology methods.
This study will provide better understanding of the effects and mechanisms of OIT and identify biomarkers for selection of patients benefitting from personalized OIT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Food Allergy, Egg Protein Allergy, Immune Tolerance
Keywords
Food allergy, Hen's egg allergy, Desensitization, Oral immunotherapy (OIT), Systems biology
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Patients are randomized 2:1 to receive active HE OIT or continue on an elimination diet after which active HE OIT is started.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hen's egg OIT
Arm Type
Active Comparator
Arm Description
Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
Arm Title
Hen's egg avoidance
Arm Type
No Intervention
Arm Description
Hen's egg is avoidance diet is continued.
Intervention Type
Dietary Supplement
Intervention Name(s)
Hen's egg OIT
Intervention Description
Increasing doses of egg white protein administered orally
Primary Outcome Measure Information:
Title
OIT-induced allergen-specific antibody responses
Description
The amount of specific serum IgE, IgG4, and IgA antibodies (kU/L) to the major egg allergens (Gal d1 - d4) will be measured by ImmunoCAP after 0, 14, and 32 weeks of OIT or avoidance.
Time Frame
Up to 32 weeks
Title
OIT-induced changes in the peripheral blood cell transcriptome
Description
Gene expression of blood mononuclear cells (PBMC) after 0, 14 and 32 weeks of OIT or avoidance will be studied. Total-RNA extracted from PBMCs will be used for microarrays. The genome-wide expression of the approximately 25.000 genes will be investigated on Agilent SurePrint G3 Human Gene Expression v3 arrays.
Time Frame
Up to 32 weeks
Title
OIT-induced allergen-specific expression profiles of messenger-RNAs and microRNAs
Description
Comprehensive highthroughput sequencing for long (mRNA) and short (miRNA) coding gene expression approach will be used to investigate transcriptional changes in exposed blood cells after different stimulations (egg extract, LPS, PolyI:C)
Time Frame
Up to 32 weeks
Secondary Outcome Measure Information:
Title
The prorportion of participants able to consume 1000mg of egg protein after 32 weeks of OIT
Description
Measured in mg of egg protein consumed without symptoms
Time Frame
Up to 32 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 6-19 years
Sensitization to egg white (egg white- specific IgE ≥0.35 kU/l or skin prick test ≥3 mm)
Positive double-blind, placebo-controlled food challenge to heated egg white
Exclusion Criteria:
Poor adherence
Uncontrolled or severe asthma
Severe systemic illness
Active autoimmune disease
Active, malignant neoplasia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mika J Mäkelä, Professor
Organizational Affiliation
Skin and Allergy Hospital, Helsinki University Central Hospital
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Immune Responses in Hen's Egg Oral Immunotherapy
We'll reach out to this number within 24 hrs